Search results for "onset"

showing 10 items of 496 documents

Effects of subchronic paroxetine administration on night-time endocrinological profiles in healthy male volunteers

2000

Abstract To evaluate the subchronic effects of paroxetine, a selective serotonin reuptake inhibitor, on nocturnal endocrinological profiles, eight healthy male volunteers with no personal or family history of a psychiatric or neurological disease were administered paroxetine (30 mg/day) or placebo in a double-blind cross-over design. Drugs were given as a single dose at 10:00 h for a period of 4 weeks each. Between days 21 and 28 of each treatment period, sleep EEG was registered for four consecutive nights from 23:00 to 07:00 h. During the last night, hormonal profiles for prolactin, growth hormone (GH), cortisol, corticotropin (ACTH), luteinizing hormone (LH), testosterone and melatonin w…

AdultMaleendocrine systemmedicine.medical_specialtyHydrocortisoneEndocrinology Diabetes and MetabolismSerotonin reuptake inhibitorPlaceboPlacebosMelatoninEndocrinologyAdrenocorticotropic HormoneDouble-Blind MethodInternal medicinemedicineHumansBiological PsychiatryMelatoninCross-Over StudiesHuman Growth HormoneEndocrine and Autonomic SystemsElectroencephalographyLuteinizing HormoneParoxetineHormonesProlactinCircadian RhythmProlactinParoxetinePsychiatry and Mental healthEndocrinologySleep onsetReuptake inhibitorPsychologyLuteinizing hormoneSelective Serotonin Reuptake Inhibitorshormones hormone substitutes and hormone antagonistsmedicine.drugPsychoneuroendocrinology
researchProduct

Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen.

2014

Abstract The aim of this randomized, crossover, comparison study was to assess the analgesic and adverse effects of 2 nasal preparations, intranasal fentanyl (INFS) and fentanyl pectin nasal spray (FPNS), for breakthrough pain, given in doses proportional to opioid basal regimen. Each patient randomly received INFS or FPNS in doses proportional to opioid dosages used for background analgesia for 2 pairs of episodes. For each episode of breakthrough pain, pain intensity and adverse effects intensity were recorded just before starting the INFS or FPNS (T0) and 5 minutes (T5), 10 minutes (T10), and 20 minutes (T20) after the administration of the nasal drugs. Sixty-nine patients were studied. …

AdultMalefentanyl pectin nasal spraymedicine.medical_treatmentAnalgesicSettore MED/42 - Igiene Generale E ApplicataFentanylrapid-onset opioidsNeoplasmsparasitic diseasesMedicineHumansCancer painAdverse effectAgedPain MeasurementAged 80 and overDose-Response Relationship Drugbusiness.industryBreakthrough Painintranasal fentanylNasal SpraysMiddle AgedCancer pain; breakthrough pain; fentanyl pectin nasal spray; intranasal fentanyl; rapid-onset opioidsAnalgesics OpioidFentanylRegimenAnesthesiology and Pain MedicineCross-Sectional StudiesNeurologyOpioidNasal sprayAnesthesiaPectinsNasal administrationFemaleNeurology (clinical)businessCancer painmedicine.drugThe journal of pain
researchProduct

Hereditary Angioedema: New Findings Concerning Symptoms, Affected Organs, and Course

2005

Abstract Purpose Hereditary angioedema (HAE) due to C1 inhibitor deficiency is clinically characterized by relapsing skin swellings, abdominal pain attacks, and life-threatening upper airway obstruction. Our aim was to examine a temporal and spatial pattern of the edema episodes by evaluating the long-term course of hereditary angioedema in order to establish a specific swelling pattern. Subjects and methods Data were generated from 221 patients with C1 inhibitor deficiency by asking them about symptoms they experienced during their edema episodes. Documentation was accomplished through the use of standardized questionnaires. Results A total of 131110 edema episodes were observed. Clinical …

AdultMalemedicine.medical_specialtyAbdominal painAdolescentLate onsetComplement C1 Inactivator ProteinsLaryngeal EdemaSeverity of Illness IndexDisease-Free SurvivalEcallantideEdemamedicineHumansAngioedemaChildSerpinsRetrospective StudiesAngioedemabusiness.industryGeneral MedicineMiddle AgedAirway obstructionmedicine.diseaseDermatologySurgeryHereditary angioedemaFemalemedicine.symptombusinessComplement C1 Inhibitor Proteinmedicine.drugThe American Journal of Medicine
researchProduct

Prevalence of residual B-cell function related to age at onset and genetic profile in newly diagnosed type I diabetics.

1987

Patients with type I (insulin-dependent) diabetes mellitus maintain B-cell function for a varying period of time after onset. This is commonly held to account for post-initial remission. To estimate residual B-cell function we measured plasma and 24-h urinary C-peptide in 68 type I diabetic patients (age range 4-35 years, within 10-180 days of the onset of symptoms, typed for HLA-A, -B, -C and DR loci. A positive correlation (r = 0.26; p less than 0.05) was found between urinary C-peptide levels and the age of the patient. The analysis of variance of urinary C-peptide values on the basis of the presence or absence of DR3 and DR4 antigens revealed that the DR3-positive patients had reduced e…

AdultMalemedicine.medical_specialtyAdolescentEndocrinology Diabetes and MetabolismUrinary systemLate onsetGastroenterologyExcretionchemistry.chemical_compoundIslets of LangerhansEndocrinologyAntigenInternal medicineDiabetes mellitusInternal MedicinemedicineHumansChildB cellC-PeptideC-peptidebusiness.industryAge FactorsGeneral MedicineHLA-DR Antigensmedicine.diseaseEndocrinologymedicine.anatomical_structureDiabetes Mellitus Type 1chemistryChild PreschoolFemaleAnalysis of variancebusinessActa diabetologica latina
researchProduct

Early onset of polyglandular failure is associated with HLA-DRB1*03.

2008

ObjectivesPolyglandular failure or autoimmunity (PGA) involves at least two endocrine diseases. Several genes may play a role in its etiology. This study analyzed 1) whether HLA-DRB1, HLA-DQB1, and MHC class I chain-related gene A (MICA) polymorphisms are associated in PGA and 2) whether PGA patients display stronger associations with these immune genes than patients with monoglandular autoimmunity (MGA).DesignAssociation study.MethodsHLA-DRB1, HLA-DQB1, and MICA alleles were analyzed in 73 patients with PGA, 283 with MGA, and 206 healthy controls. The HLA-DRB1 and HLA-DQB1 polymorphisms were determined with PCR-amplified DNA being hybridized with PCR-sequence-specific oligonucleotide probe…

AdultMalemedicine.medical_specialtyAdolescentGenotypeEndocrinology Diabetes and MetabolismBiologymedicine.disease_causePolymerase Chain Reactionlaw.inventionAutoimmunityEndocrinologyGene FrequencylawInternal medicineGermanyHLA-DQ AntigensmedicineHLA-DQ beta-ChainsHumansGenetic Predisposition to DiseaseAlleleAge of OnsetChildPolyendocrinopathies AutoimmuneGeneHLA-DRB1Polymerase chain reactionAllelesPolymorphism GeneticHistocompatibility Antigens Class IGeneral MedicineHLA-DR AntigensMiddle AgedEndocrinologyGenetic markerMicrosatelliteFemaleAge of onsetHLA-DRB1 ChainsEuropean journal of endocrinology
researchProduct

Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management

2011

The mucopolysaccharidoses (MPSs) are inherited lysosomal storage disorders caused by the absence of functional enzymes that contribute to the degradation of glycosaminoglycans (GAGs). The progressive systemic deposition of GAGs results in multi-organ system dysfunction that varies with the particular GAG deposited and the specific enzyme mutation(s) present. Cardiac involvement has been reported in all MPS syndromes and is a common and early feature, particularly for those with MPS I, II, and VI. Cardiac valve thickening, dysfunction (more severe for left-sided than for right-sided valves), and hypertrophy are commonly present; conduction abnormalities, coronary artery and other vascular in…

AdultMalemedicine.medical_specialtyAdolescentMucopolysaccharidosisClinical SciencesHeart Valve DiseasesReviewComorbidityCoronary Artery DiseaseDiseaseMuscle hypertrophyCoronary artery diseaseElectrocardiographyVentricular hypertrophyTachycardiaInternal medicineGeneticsmedicineHumansGenetics(clinical)Age of OnsetSinusChildPreschoolGenetics (clinical)GlycosaminoglycansGenetics & Hereditymedicine.diagnostic_testbusiness.industryMitral Valve InsufficiencyHypertrophyAortic Valve StenosisEnzyme replacement therapyMucopolysaccharidosesMiddle Agedmedicine.diseaseLeft VentricularCausalityTachycardia SinusEchocardiographyChild PreschoolAortic valve stenosisCardiologyHypertrophy Left VentricularFemalebusinessElectrocardiographyJournal of Inherited Metabolic Disease
researchProduct

Trends in excess mortality in follicular lymphoma at a population level

2015

Background Since the 1990s and since the development of humanised monoclonal antibodies in 1998, the treatment of non-Hodgkin lymphoma has undergone profound changes. Follicular lymphoma (FL) was the first to benefit from this treatment, and several clinical trials have shown a significant improvement in overall survival, but little information is available at a population level. Objective Our objective was to estimate changes in FL-specific mortality at a population level, with an appropriate methodology. Methods Two French retrospective population-based studies on FL were conducted, one from 1995 to 2004, in 1477 patients, and one from 1995 to 2010, in 451 patients. Trends in excess morta…

AdultMalemedicine.medical_specialtyAdolescentPopulation level[SDV]Life Sciences [q-bio]PopulationFollicular lymphomaHistory 21st CenturyYoung Adult03 medical and health sciences0302 clinical medicineInternal medicineHumansMedicineIn patientRegistriesAge of OnsetStage (cooking)educationLymphoma FollicularAgedNeoplasm StagingRetrospective StudiesAged 80 and overExcess mortalityeducation.field_of_studybusiness.industryHematologyGeneral MedicineHistory 20th CenturyMiddle Agedmedicine.disease3. Good healthLymphomaClinical trialPopulation Surveillance030220 oncology & carcinogenesisImmunologyFemaleFrancebusiness030215 immunology
researchProduct

Central nervous system involvement in late-onset Pompe disease: clues from neuroimaging and neuropsychological analysis

2018

Background and purpose Late-onset Pompe disease (LOPD) is a rare, multisystem disorder that is well established to mainly impair skeletal muscle function. Systematic studies exploring brain functions in LOPD are lacking. The aim of this study was to detect morphological and functional brain alterations as well as neuropsychological impairment in LOPD. Methods We studied 21 patients (10 male, mean age 49 ± 18.4 years) with defined diagnosis of LOPD, divided into two groups: one with pre-symptomatic hyperCKemia with no muscle weakness and the second with limb-girdle muscle weakness. All patients underwent 3T magnetic resonance imaging (MRI) to obtain morphological/angiographic evaluation as w…

AdultMalemedicine.medical_specialtyAdolescentSmoker scoreNeuropsychological Testscerebrovascular abnormalitieslate-onset Pompe diseaseYoung Adult03 medical and health sciences0302 clinical medicineAtrophyNeuroimagingInternal medicineConnectomemedicinecerebrovascular abnormalities Fazekas score functional magnetic resonance imaging late-onset Pompe disease Pompe disease Smoker score Neurology Neurology (clinical)HumansCognitive Dysfunction030212 general & internal medicineNeuropsychological assessmentAge of OnsetGray MatterAgedmedicine.diagnostic_testGlycogen Storage Disease Type IIbusiness.industryMuscle weaknessPompe diseaseMagnetic resonance imagingMiddle Agedmedicine.diseaseMagnetic Resonance Imagingfunctional magnetic resonance imagingHyperintensityFazekas scoreSuperior frontal gyrusNeurologyBrain sizeCardiologyFemaleNeurology (clinical)medicine.symptombusiness030217 neurology & neurosurgery
researchProduct

Global and regional cortical thinning in first-episode psychosis patients: relationships with clinical and cognitive features

2010

BackgroundThe thickness of the cortical mantle is a sensitive measure for identifying alterations in cortical structure. We aimed to explore whether first episode schizophrenia patients already show a significant cortical thinning and whether cortical thickness anomalies may significantly influence clinical and cognitive features.MethodWe investigated regional changes in cortical thickness in a large and heterogeneous sample of schizophrenia spectrum patients (n=142) at their first break of the illness and healthy controls (n=83). Magnetic resonance imaging brain scans (1.5 T) were obtained and images were analyzed by using brains2. The contribution of sociodemographic, cognitive and clinic…

AdultMalemedicine.medical_specialtyAdolescentbrainBrain mappingArticleYoung AdultCognitionCortex (anatomy)Internal medicineImage Processing Computer-AssistedmedicineHumansApplied PsychologyCerebral CortexPsychiatric Status Rating ScalesAnalysis of VarianceBrain Mappingmedicine.diagnostic_testAge FactorsMagnetic resonance imagingMiddle Agedcortical thicknessmedicine.diseaseMagnetic Resonance ImagingendophenotypeschizophreniaPsychiatry and Mental healthmedicine.anatomical_structureCerebral cortexSchizophreniaEndophenotypeCardiologyFemaleAnalysis of varianceAge of onsetPsychologyNeuroscienceMRIPsychological Medicine
researchProduct

Progressive cerebellar ataxia, proximal neurogenic weakness and ocular motor disturbances: hexosaminidase A deficiency with late clinical onset in fo…

1997

Tay-Sachs disease is a genetically determined neurodegenerative disorder, resulting from mutations of the hexosaminidase (Hex) A gene coding for the alpha-subunit of beta-D-N-acetyl-hexosaminidase. Clinically, there is severe encephalomyelopathy leading to death within the first few years of life. Hex A activity is usually absent in tissue and body fluids of these patients. Juvenile and adult Hex A deficiencies are less severe but rare variants with some residual Hex A activity. All these variants are most prevalent among Ashkenazi Jews. We describe a non-Jewish family in which four adult brothers and sisters had markedly reduced Hex A activities and onset of symptoms in the second decade o…

AdultMalemedicine.medical_specialtyAtaxiaCerebellar AtaxiaEye MovementsBiopsyNeural ConductionCompound heterozygosityNuclear FamilyHexosaminidase AInternal medicinemedicineHumansHexosaminidaseAge of OnsetMotor Neuron DiseaseSkinMuscle WeaknessTay-Sachs Diseaseintegumentary systemTay-Sachs diseaseSpinal muscular atrophyDNAExonsmedicine.diseaseMagnetic Resonance ImagingAshkenazi jewsbeta-N-AcetylhexosaminidasesPedigreecarbohydrates (lipids)EndocrinologyPhenotypeNeurologyOculomotor MusclesCerebellar atrophyFemaleNeurology (clinical)Age of onsetmedicine.symptomPsychologyJournal of the neurological sciences
researchProduct